Due to the technical evolution of radiation therapy of breast carcinoma, new manifestations occur as side effects. Newly described unexpected cutaneous events are morphea of the breast and pseudosclerodermatous panniculitis after irradiation (PPAI). They appear as specific consequences of megavoltage radiation. Radiotherapy-induced bronchiolitis obliterans organizing pneumonia (R-BOOP) is one of the pulmonary manifestations due to recent advances in radiotherapy of breast carcinoma. We report a case of PPAI and R-BOOP of simultaneous onset in a 60-year-old woman 6 months after megavoltage radiation therapy for breast carcinoma. We also noted an improvement of both unexpected reactions with systemic corticosteroid therapy and a common relapse when tapering the treatment. Only eight cases of PPAI have previously been reported. We believe that this entity is often underdiagnosed. The symmetrical onset and parallel evolution suggest a common origin for PPAI and BOOP in our case: the megavoltage radiation therapy. The pathogeny of R-BOOP is not direct toxicity of irradiation because untreated areas can also be affected. Pathogenesis of PPAI remains unknown, but a simultaneous onset with R-BOOP suggests a similar mechanism. While a cumulative dose of irradiation does not seem to be determinant an immune reaction to neoantigens induced by radiation could be an hypothesis.

Crestani B, Kambouchner M, Soler P, Crequit J, Brauner M, Battesti JP, Valeyre D: Migratory bronchiolitis obliterans organizing pneumonia after unilateral radiation therapy for breast carcinoma. Eur Respir J 1995;8:318–321.
Epler GR: Bronchiolitis obliterans organizing pneumonia. Arch Intern Med 2001;161:158–164.
Crestani B, Valeyre D, Roden S, Wallaret B, Dalphin JC, Cordier JF: Bronchiolitis obliterans organizing pneumonia primed by radiation therapy to the breast. Am J Respir Crit Care Med 1998;158:1929–1935.
Nambu A, Araki T, Ozawa K, Kanazawa M, Ohki Z, Miyata K: Bronchiolitis obliterans organizing pneumonia after tangential beam irradiation to the breast: Discrimination from radiation pneumonitis. Radiat Med 2002;20:151–154.
Takigawa N, Segawa Y, Saeki T, Kataoka M, Ida M, Kishino D, Fujiwara K, Ohsumi S, Eguchi K, Takashima S: Bronchiolitis obliterans organizing pneumonia syndrome in breast-conserving therapy for early breast cancer: Radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys 2000;48:751–755.
Winkelmann RK, Grado GL, Quimby SR, Connolly SM: Pseudosclerodermatous panniculitis after irradiation: An unusual complication of megavoltage treatment of breast carcinoma. Mayo Clin Proc 1993;68:122–127.
Requena L, Sanchez Yus E: Panniculitis. II. Mostly lobular panniculitis. J Am Acad Dermatol 2001;45:325–364.
Carrasco L, Moreno C, Pastor MA, Izquierdo MJ, Farina C, Martin L, Sangueza OP, Requena L: Postirradiation pseudosclerodermatous panniculitis. Am J Dermatopathol 2001;23:283–287.
James WD, Odom RB: Late subcutaneous fibrosis following megavoltage radiotherapy. J Am Acad Dermatol 1980;3:616–618.
Bleasel NR, Stapleton KM, Commens C, Ahern VA: Localized scleroderma in breast cancer patients. Australas J Dermatol 1999;40:99–102.
Davis DA, Cohen PR, McNeese MD, Duvic M: Localized scleroderma in breast cancer patients treated with supervoltage external beam radiation: Radiation port scleroderma. J Am Acad Dermatol 1996;35:923–927.
Colver GB, Rodger A, Mortimer PS, Savin JA, Neill SM, Hunter JAA: Post-irradiation morphea. Br J Dermatol 1989;120 :831–835.
Schaffer JV, Carroll C, Dvoretsky I, Huether MJ, Girardi M: Postirradiation morphea of the breast presentation of two cases and review of the literature. Dermatology 2000;200:67–71.
Ng PP, Tan SH, Tan T: Lupus erythematosus panniculitis: A clinicopathologic study. Int J Dermatol 2002;41:488–490.
Majori M, Poletti V, Curti A, Corradi M, Falcone F, Pesci A: Bronchoalveolar lavage in bronchiolitis obliterans organizing pneumonia primed by radiation therapy to the breast. J Allergy Clin Immunol 2000;105:239–244.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.